Infant Bacterial Therapeutics (IBT:LSE) Annual Reports & Investor Relations Material

Overview

International Biotechnology Trust (IBT) is an investment firm that focuses on development and late-stage companies in the biotechnology and life sciences sectors. The majority of the fund's investments are in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. IBT invests in companies engaged in the development and commercialization of biotechnology drug candidates, medical devices, and other enabling technologies. The firm typically invests in the United States but seeks the best investments worldwide, including Western Europe, Australia, and Asia. IBT exits unquoted investments through the sale of these companies to strategic buyers or through a flotation.

Frequently Asked Questions

What is Infant Bacterial Therapeutics's ticker?

Infant Bacterial Therapeutics's ticker is IBT

What exchange is Infant Bacterial Therapeutics traded on?

The company's shares trade on the LSE stock exchange

Where are Infant Bacterial Therapeutics's headquarters?

They are based in London, England

How many employees does Infant Bacterial Therapeutics have?

There are 1-10 employees working at Infant Bacterial Therapeutics

What is Infant Bacterial Therapeutics's website?

It is ibtherapeutics.com

What type of sector is Infant Bacterial Therapeutics?

Infant Bacterial Therapeutics is in the Financial sector

What type of industry is Infant Bacterial Therapeutics?

Infant Bacterial Therapeutics is in the Asset Management industry

Who are Infant Bacterial Therapeutics's peers and competitors?

The following five companies are Infant Bacterial Therapeutics's industry peers:

- Almirall

- Ironbark Capital Limited

- Blucora

- Prospect Capital

- AssetMark Financial